Because it wasn't involved.
From a quick look, PAB's announcement says that their nanoparticles conjugated to PAT-DX1 (PAT-DX1-NP) has shown improved targeting of glioblastomas in mice. They are excited because this suggests it might be used both to deliver their PAT-X1 drug but also as a vector for introducing other targeted treatments to brain tumours.
AB is pointing to their 2016 post, which refers to the DEP Docetaxel clinical program phase 1 clinical trial, which showed efficacy signals on a variety of tumour types including glioblastomas.
The PAB announcement is unrelated to SPL (unless PAB is a silent partner of SPL using DEP but I don't know anything to suggest they are).
AB is just drawing a comparison.
- Forums
- ASX - By Stock
- SPL
- Starpharma and Glioblastoma and Dep Docetaxel and Patrys
Starpharma and Glioblastoma and Dep Docetaxel and Patrys, page-6
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M |
Open | High | Low | Value | Volume |
10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 83046 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 83046 | 0.105 |
3 | 198569 | 0.100 |
1 | 10111 | 0.099 |
3 | 483557 | 0.096 |
1 | 824859 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 30000 | 1 |
0.115 | 122753 | 4 |
0.120 | 221197 | 6 |
0.125 | 30000 | 1 |
0.130 | 138570 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online